Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance.)

Amendment to Regulation (EC) No 1272/2008

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Correction to Regulation (EU) 2017/776

Article 2

In Regulation (EU) 2017/776, the second subparagraph of Article 2(2) is replaced by the following: ‘In the Annex, point (1), point (2) and points (a), (b) and (c) of point (3) shall apply from 1 June 2017.’

Entry into force and application

Article 3

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . Point (1) and point (a) of point (2) of the Annex shall apply from 1 December 2019. Points (b), (c), (d) and (e) of point (2) of the Annex shall apply from 1 May 2020. By way of derogation from the third paragraph of this Article, substances and mixtures may, before 1 May 2020, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

ANNEXSupplementary provisions

ANNEX Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) in Part 1, the heading of point 1.1.1.4 is replaced by the following: ‘ Chemical name ’; (2) in Part 3, Table 3.1 is amended as follows: (a) the title of the second column is replaced by the following: ‘Chemical name’; (b) the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*) (*) ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’; (c) the entry corresponding to index number 607-414-00-6 is deleted; (d) the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively: Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘006-044-00-7 isoproturon (ISO); 3-(4-isopropylphenyl)-1,1-dimethylurea 251-835-4 34123-59-6 Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H373 (blood) H400 H410 GHS08 GHS09 Wng H351 H373 (blood) H410   M = 10 M = 10’   ‘015-101-00-5 phosmet (ISO); S -[(1,3-dioxo-1,3-dihydro-2 H -isoindol-2-yl)methyl] O , O -dimethyl phosphorodithioate; O , O -dimethyl- S -phthalimidomethyl phosphorodithioate 211-987-4 732-11-6 Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H361f H332 H301 H370 (nervous system) H400 H410 GHS08 GHS06 GHS09 Dgr H361f H332 H301 H370 (nervous system) H410   M = 100 M = 100’   ‘016-096-00-2 thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate — 79277-27-3 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 100 M = 100’   ‘017-011-00-1 sodium hypochlorite, solution … % Cl active 231-668-3 7681-52-9 Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H314 H318 H400 H410 GHS05 GHS09 Dgr H314 H410 EUH031 M = 10 M = 1 EUH031: C ≥ 5 % B’ ‘025-002-00-9 potassium permanganate 231-760-3 7722-64-7 Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 H272 H361d H302 H400 H410 GHS03 GHS08 GHS07 GHS09 Dgr H272 H361d H302 H410’       ‘603-180-00-4 colecalciferol; cholecalciferol; vitamin D 3 200-673-2 67-97-0 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 H330 H310 H300 H372 GHS06 GHS08 Dgr H330 H310 H300 H372     inhalation: ATE = 0,05 mg/L (dusts or mists)   dermal: ATE = 50 mg/kg bw   oral: ATE = 35 mg/kg bw STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 %’   ‘604-014-00-3 chlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol 200-431-6 59-50-7 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 3 H302 H314 H318 H335 H317 H400 H412 GHS07 GHS05 GHS09 Dgr H302 H314 H335 H317 H410   M = 1’   ‘604-016-00-4 1,2-dihydroxybenzene; pyrocatechol 204-427-5 120-80-9 Carc. 1Β Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2 H350 H341 H311 H301 H315 H319 GHS08 GHS06 Dgr H350 H341 H311 H301 H315 H319     oral: ATE = 300 mg/kg bw   dermal: ATE = 600 mg/kg bw’   ‘604-090-00-8 4- tert -butylphenol 202-679-0 98-54-4 Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 1 H361f H315 H318 H410 GHS08 GHS05 GHS09 Dgr H361f H315 H318 H410   M = 1’   ‘605-003-00-6 acetaldehyde; ethanal 200-836-8 75-07-0 Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2 H224 H350 H341 H335 H319 GHS02 GHS08 GHS07 Dgr H224 H350 H341 H335 H319’       ‘606-047-00-9 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone 404-360-3 119313-12-1 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360D H400 H410 GHS08 GHS09 Dgr H360D H410’       ‘607-096-00-9 maleic anhydride 203-571-6 108-31-6 Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A H302 H372 (respiratory system) (inhalation) H314 H318 H334 H317 GHS07 GHS08 GHS05 Dgr H302 H372 (respiratory system) (inhalation) H314 H334 H317 EUH071 Skin Sens. 1A; H317: C ≥ 0,001 %’   ‘607-103-00-5 succinic anhydride 203-570-0 108-30-5 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 H302 H314 H318 H334 H317 GHS07 GHS05 GHS08 Dgr H302 H314 H334 H317 EUH071’     ‘607-113-00-X isobutyl methacrylate 202-613-0 97-86-9 Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B H226 H335 H315 H317 GHS02 GHS07 Wng H226 H335 H315 H317     D’ ‘607-373-00-4 quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate 414-200-4 200509-41-7 Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361fd H302 H373 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361fd H302 H373 H410   M = 1 M = 1’   ‘613-167-00-5 reaction mass of 5-chloro-2-methyl-2 H -isothiazol-3-one and 2-methyl-2 H -isothiazol-3-one (3:1) — 55965-84-9 Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H310 H301 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H310 H301 H314 H317 H410 EUH071 Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 B’ ‘613-205-00-0 propiconazole (ISO); (2 RS ,4 RS ;2 RS ,4 SR )-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1 H -1,2,4-triazole 262-104-4 60207-90-1 Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H360D H302 H317 H410   M = 1 M = 1’   ‘614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 H330 H310 H300 H411 GHS06 GHS09 Dgr H330 H310 H300 H411     inhalation: ATE = 0,19 mg/L (dusts or mists)   dermal: ATE = 70 mg/kg bw   oral: ATE = 5 mg/kg bw’   (e) the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1: Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘604-094-00-X isoeugenol; [1] ( E )-2-methoxy-4-(prop-1-enyl)phenol; [2] ( Z )-2-methoxy-4-(prop-1-enyl)phenol [3] 202-590-7 [1] 227-678-2 [2] 227-633-7 [3] 97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] Skin Sens. 1A H317 GHS07 Wng H317   Skin Sens. 1A; H317: C ≥ 0,01 %’   ‘607-724-00-1 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1 R ,3 R )-2,2-dimethyl-3-[(1 Z )-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin — 240494-71-7 Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H301 H370 (nervous system) H373 H400 H410 GHS06 GHS08 GHS09 Dgr H332 H301 H370 (nervous system) H373 H410   M = 100 M = 100’   ‘607-725-00-7 isopropyl (2 E ,4 E ,7 S )-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S -methoprene — 65733-16-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 M = 1’   ‘607-726-00-2 pinoxaden (ISO); 8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7 H -pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate — 243973-20-8 Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3 H361d H332 H302 H319 H335 H317 H400 H412 GHS08 GHS07 GHS09 Wng H361d H332 H302 H319 H335 H317 H410     inhalation: ATE = 4,63 mg/L (dusts or mists)   oral: ATE = 500 mg/kg bw M = 1’   ‘607-727-00-8 tetramethrin (ISO); (1,3-dioxo-1,3,4,5,6,7-hexahydro-2 H -isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate 231-711-6 7696-12-0 Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H371 (nervous system) (inhalation) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H371 (nervous system) (inhalation) H410   M = 100 M = 100’   ‘607-728-00-3 (1,3,4,5,6,7-hexahydro-1,3-dioxo- 2H -isoindol-2-yl)methyl (1 R - trans )-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate 214-619-0 1166-46-7 Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H371 (nervous system) (inhalation) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H371 (nervous system) (inhalation) H410   M = 100 M = 100’   ‘607-729-00-9 mesosulfuron-methyl (ISO); methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)- p -toluate; — 208465-21-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 100 M = 100’   ‘607-730-00-4 spirodiclofen (ISO); 3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate — 148477-71-8 Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 H350 H361f H373 H317 H410 GHS08 GHS07 GHS09 Dgr H350 H361f H373 H317 H410   M = 10’   ‘607-731-00-X sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl ( EZ )-sulfanilylcarbonimidate; asulam-sodium 218-953-8 2302-17-2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410   M = 1 M = 1’   ‘607-732-00-5 salicylic acid 200-712-3 69-72-7 Repr. 2 Acute Tox. 4 Eye Dam. 1 H361d H302 H318 GHS08 GHS07 GHS05 Dgr H361d H302 H318’       ‘608-068-00-9 flutianil (ISO); (2 Z )-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile — 958647-10-4 Aquatic Chronic 1 H410 GHS09 Wng H410   M = 100’   ‘612-293-00-8 reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine 447-920-2 - Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 H361f H302 H314 H318 GHS08 GHS07 GHS05 Dgr H361f H302 H314 EUH071’     ‘613-326-00-9 2-methylisothiazol-3(2 H )-one 220-239-6 2682-20-4 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H311 H301 H314 H318 H317 H400 H410 GHS05 GHS06 GHS09 Dgr H330 H311 H301 H314 H317 H410 EUH071 Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1’   ‘613-327-00-4 pyroxsulam (ISO); N -(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide — 422556-08-9 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410   M = 100 M = 100’   ‘613-328-00-X 1-vinylimidazole 214-012-0 1072-63-5 Repr. 1B H360D GHS08 Dgr H360D   Repr. 1B; H360D: C ≥ 0,03 %’   ‘616-224-00-2 amisulbrom (ISO); 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)- N,N -dimethyl-1 H -1,2,4-triazole-1-sulfonamide — 348635-87-0 Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H319 H400 H410 GHS08 GHS07 GHS09 Wng H351 H319 H410   M = 10 M = 10’